FilingIndex
8-KThe WireRoutine

Bylaw Amendment

Filed Sep 10, 2024 · 1y ago · Accession 0001104659-24-098564

Plain English

Material event — a significant development the company must disclose promptly.

Read the source below for the full document.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549       FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 6, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨   Common Stock, $0.01 Par Value ABBV         Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year   On September 6, 2024, the Board of Directors of AbbVie Inc. (the “Company”) approved an amendment and restatement of the Company’s By-laws (the “Third Amended and Restated By-laws”), effective as of such date.   The amendments set forth in the Third Amended and Restated By-laws, (1) update the address of Company’s registered agent, and (2) delete section 2.13(D)(iv) in its entirety. Company is the defendant in a stockholder class action complaint challenging the lawfulness of Section 2.13(D)(iv). Company believes the provision is lawful but no longer has any practical value to the Company. Accordingly, Company does not believe defending this provision is the best use of company resources.    The foregoing summary of the Third Amended and Restated By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amended and Restated By-laws, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits   (d) Exhibits   Exhibit No.   Exhibit 3.1   Third Amended and Restated By-laws of AbbVie Inc. adopted September 6, 2024. 104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101)         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.         ABBVIE INC.         Date: September 10, 2024 By: /s/ Perry C. Siatis       Perry C. Siatis       Executive Vice President, General       Counsel and Secretary
Filing details
Ticker
ABBV
CIK
1551152
Form type
8-K
Filing date
Sep 10, 2024
Report date
Sep 6, 2024
Document
tm2423380d1_8k.htm
Size
535 KB